Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts

详细信息    查看全文

• 作者：Adam D. Swick^a ; ¹ ; Andrew P. Stein^a ; ¹ ; Timothy M. McCulloch^d ; ^e ; Gregory K. Hartig^d ; ^e ; Irene M. Ong^b ; ^e ; Emmanuel Sampene^b ; Prashanth J. Prabakaran^a ; Cheng Z. Liu^c ; Randall J. Kimple^a ; ^e ; ^{rkimple@humonc.wisc.edu}
• 关键词：Head and neck cancer ; HNSCC ; Patient derived xenograft ; PDX ; Mouse model
• 刊名：Oral Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：64
• 期：Complete
• 页码：65-72
• 全文大小：1064 K
• 卷排序：64

文摘

Head and neck cancer PDXs can be generated for a wide range of tumor characteristics. A 24-h delay post surgical resection does not impact engraftment rate. Protein expression biomarkers are stable across PDX passages. Mutational profile of PDXs are stable from patient tumor to multiple PDX generations.